Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
Alimentary Pharmacology & Therapeutics · 2024-09 · 60 (5) · 620-632
DOI: 10.1111/apt.18138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 27.06.2024. Verfasst von Aakash Desai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Colitis, Ulcerative, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) show anti‐inflammatory properties.
Aim
To evaluate their clinical impact on inflammatory bowel disease (IBD) outcomes.
Methods
Retrospective cohort study utilising the TriNetX database comparing IBD‐specific outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) and type 2 diabetes mellitus (T2DM) on GLP‐1RA compared to oral hypoglycaemic agents. The primary outcome was hospitalisation requiring intravenous steroids and IBD‐related surgery within 3 years. We performed 1:1 propensity score matching (PSM) for demographics, co‐morbid conditions, BMI, laboratory values, HbA1c, and IBD medications including steroids.
Results
We identified 1130 patients in the UC GLP‐1RA cohort (mean age: 58.9 ± 11.6 years, 56.3% female, 70.2% White, 57.2% with obesity) and 1140 patients in the CD GLP‐1RA cohort (mean age: 56.7 ± 11.5, 61.9% female, 73.6% White, 56.2% with obesity). After PSM, there was no difference in the risk of intravenous steroid use (aHR: 1.21, 95% CI: 0.92–1.59) but a lower risk of colectomy (aHR: 0.37, 95% CI: 0.14–0.97) between the UC GLP‐1RA and control cohort. There was no difference in the risk of intravenous steroid use (aHR: 1.04, 95% CI: 0.80–1.34) but a lower risk of surgery (aHR: 0.55, 95% CI: 0.36–0.84) between the CD GLP‐1RA and CD control cohort. There was no difference in the risk of oral steroid use or advanced therapy initiation in the UC and CD GLP‐1RA than control cohorts.
Conclusions
We found an association between lower risk of IBD‐related surgery and GLP‐1RA use for T2DM in patients with UC or CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Gastroenterology and Hepatology, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Division of Gastroenterology & Hepatology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Aakash Desai, Gursimran S Kochhar
Zitieren
APA
Desai, A., Petrov, J., Hashash, J. G., Patel, H., Brahmbhatt, B., Kochhar, G. S., & Farraye, F. A. (2024). Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 60(5), 620-632. https://doi.org/10.1111/apt.18138
Vancouver
Desai A, Petrov J, Hashash JG, Patel H, Brahmbhatt B, Kochhar GS, et al. Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2024;60(5):620-632. doi:10.1111/apt.18138
BibTeX
@article{Desai2024,
author = {Desai, Aakash and Petrov, Jessica and Hashash, Jana G and Patel, Harsh and Brahmbhatt, Bhaumik and Kochhar, Gursimran S and Farraye, Francis A},
title = {Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {5},
pages = {620--632},
doi = {10.1111/apt.18138}
}
EUVIMED